The C677T polymorphism in the MTHFR gene is associated with the toxicity of methotrexate in a Spanish rheumatoid arthritis population

Scandinavian Journal of Rheumatology

Volumn 41, Issue 1, 2012, Pages 10-14

  Caliz R ^a   Del Amo, J ^b   Balsa, A ^c   Blanco, F ^d   Silva, L ^e   Sanmarti, R ^f   Martnez, F G ^g   Collado, M D ^a   Del Carmen Ramirez, M ^a   Tejedor, D ^b   Artieda, M ^b   Pascual Salcedo, D ^c   Oreiro, N ^d   Andreu, J L ^e   Graell, E ^f   Simon, L ^b   Martinez A ^b   Mulero, J ^e  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b Progenika Biopharma SA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d HOSPITAL JUAN CANALEJO   (Spain)

^e HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE; CYSTEINE; FOLIC ACID; METHOTREXATE; OLIGONUCLEOTIDE; THREONINE;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SPAIN; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; SPAIN;

EID: 84856410726     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2011.617312     Document Type: Article

References (33)

1. Rath T, Rubbert A. Drug combinations with methotrexate to treat rheumatoid arthritis. Clin Exp Rheumatol 2010;28:S52-7.
2. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004;50:1370-82. (Pubitemid 38608058)
3. Jones G, Halbert J, CrottyM, Shanahan EM, Batterham M, Ahern M. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo controlled trials. Rheumatology (Oxford) 2003;42:6-13. (Pubitemid 36131560)
4. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, et al. Evidence from clinical trials and long-term observational studies that disease modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) 2002;41:1346-56. (Pubitemid 36004310)
5. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990;33:1449-61. (Pubitemid 20362087)
6. de Thurah A, Nørgaard M, Johansen M, Stengaard-Pedersen K. Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital. Scand J Rheumatol 2010;39:19-25.
7. Weisman MH, Furst DE, Park GS, Kremer JM, Smith KM, Wallace DJ, et al. Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis. Arthritis Rheum 2006;54:607-12. (Pubitemid 43228638)
8. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) 2002;41:1367-74. (Pubitemid 36004312)
9. SöderlinMK, Lindroth Y, Turesson C, Jacobsson LT. A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997-2005. Scand J Rheumatol 2010;39:206-11.
10. Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol Suppl 1985;12(Suppl 12):35-9. (Pubitemid 16082378)
11. Wernick R, Smith DL. Central nervous system toxicity associated with weekly low-dose methotrexate treatment. Arthritis Rheum1989;32:770-5. (Pubitemid 19179257)
12. McKendry RJ, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993;20:1850-6. (Pubitemid 24031586)
13. Kerstens PJ, Boerbooms AM, Jeurissen ME, Fast JH, Assmann KJ, van de Putte LB. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases. J Rheumatol 1992;19:867-71.
14. Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 1987;16:186-95. (Pubitemid 17029070)
15. Aggarwal P, Naik S, Mishra KP, Aggarwal A, Misra R. Correlation between methotrexate efficacy and toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. Indian J Med Res 2006;124:521-6. (Pubitemid 46157711)
16. Kim SK, Jun JB, El-Sohemy A, Bae SC. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 2006;33:1266-74. (Pubitemid 44025139)
17. Wessels JA, de Vries-Bouwstra JK, Heijmans BT, Slagboom PE, Goekoop-Ruiterman YP, Allaart CF, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006;54:1087-95. (Pubitemid 43672921)
18. van Ede AE, Laan RF, Blom HJ, Huizinga TW, Haagsma CJ, Giesendorf BA, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 2001;44:2525-30. (Pubitemid 33049330)
19. Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E, et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics 2007;17:383-90. (Pubitemid 46763383)
20. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int J Mol Med 2003;11:593-600.
21. Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T, et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 2004; 63:1227-31. (Pubitemid 39273498)
22. Kurzawski M, Pawlik A, Safranow K, Herczynska M, Drozdzik M.677C>T and 1298A>CMTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics 2007;8:1551-9. (Pubitemid 350286399)
23. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002;12:183-90. (Pubitemid 34596782)
24. Haagsma CJ, Blom HJ, van Riel PL, van't HofMA, Giesendorf BA, van Oppenraaij-Emmerzaal D, et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58:79-84. (Pubitemid 29116306)
25. Fisher MC, Cronstein BN. Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 2009;36:539-45.
26. Lee YH, Song GG. Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin Drug Investig 2010;30:101-8.
27. Balsa A, Del Amo J, Blanco F, Caliz R, Silva L, Sanmarti R, et al. Prediction of functional impairment and remission in rheumatoid arthritis patients by biochemical variables and genetic polymorphisms. Rheumatology (Oxford) 2010;49:458-66.
28. Tejedor D, Castillo S, Mozas P, Jiménez E, López M, Tejedor MT, et al. Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 2005;51:1137-44. (Pubitemid 43079390)
29. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195-201. (Pubitemid 32244306)
30. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-72. (Pubitemid 28453294)
31. Dervieux T, Wessels JA, van der Straaten T, Penrod N, Moore JH, Guchelaar HJ, et al. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet Genomics 2009;19:935-44.
32. Hoekstra M, van Ede AE, Haagsma CJ, van de Laar MA, Huizinga TW, Kruijsen MW, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423-6. (Pubitemid 36469732)
33. de Thurah A, Nørgaard M, Johansen MB, Stengaard-Pedersen K. Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study. Scand J Rheumatol 2010;39:197-205.